The SYGNAL (Systems Genetic Network Analysis) technology underlying the SPOT-AI platform was developed by our cofounder Dr. Nitin Baliga at the Institute for Systems Biology (ISB).

Utilizing that technology, Baliga and serial entrepreneur Ashutosh Tiwary founded Sygnomics in 2020, after Tiwary spent two years as an Entrepreneur in Residence at ISB.

Using gifts from the Washington Research Foundation, along with a $2M technology commercialization grant from the Washington State Andy Hill Care Fund in 2023, Sygnomics performed preliminary clinical validations, which showed that SPOT-AI can provide an end-to-end service that addresses an unmet need helping oncologists build personalized therapies for each patient.

In October 2023, Sygnomics was chosen to participate in the Computational Health stream of the Creative Destruction Labs (CDL) incubator. We’ve benefited tremendously from the advice and guidance of mentors with deep domain expertise in oncology, genomic testing, clinical trials, drug commercialization, and regulatory and payer approval processes. These mentors have helped us define and build our product offerings, our commercialization strategy, and our business plan—all of which have been vetted four times with the broad CDL team of mentors and investors.